This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

€500 savings end in:

  • 00
  • 00
  • 00
  • 00
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering



With over 15 years of dedicated research, React4Life is at the forefront of scientific innovation, channeling its efforts to transform biomedical advancements into tangible benefits for mankind. Nowadays, medical research still struggles with a long-standing problem related to unpredictable drug testing and poor human disease knowledge. 80% of drugs fail clinical tests, so the average time for a drug to come to market is about 12 years, leading to a cost of about 1$ billion (for every single drug). This problem is mainly due to a wrong drug selection in the pre-clinical phase. Indeed, scientists are missing reliable disease models to advance research. The general discontent is related to the faults of available models, unable to capture the complexity of human disease. To address this urgent need for advanced in vitro alternatives, more clinically relevant and closer to human physiology than animal models, React4life developed and industrialized MIVO® - Multi In Vitro Organ, an innovative organ-on-chip technology able to emulate human organs in the lab. In the last two years, our unwavering commitment has been directed toward the revolutionary application of the patented MIVO® technology in the dynamic field of immunooncology. This strategic pursuit not only addresses the limitations of current pre-clinical phases but also aligns with ethical considerations by substantially reducing reliance on animal testing, ushering in a new era of more predictive results within human models.